- /
- Supported exchanges
- / XETRA
- / MRK.XETRA
Merck KGaA (MRK XETRA) stock market data APIs
Merck KGaA Financial Data Overview
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Merck KGaA (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Merck KGaA data using free add-ons & libraries
Get Merck KGaA Fundamental Data
Merck KGaA Fundamental data includes:
- Net Revenue: 21 219 M
- EBITDA: 5 953 M
- Earnings Per Share: 6
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: 2.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck KGaA News
New
Merck KGaA, Darmstadt, Germany Signs Long-Term Renewable Energy Contract for South Korea Sites
20-year Power Purchase Agreement with SK Innovation E&S to add 16 MW of renewable electricity capacity starting in December 2027 Supports company's 2030 sustainability targets to source 80% renewable ...
Assessing Merck KGaA’s Share Price After New Cancer Therapy Collaboration and Market Dip
Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same questio...
Green Chemicals Market Size | Companies Analysis 2025- 2034
Precedence Research According to Towards Chemical and Materials, the global green chemicals market size is calculated at USD 14.94 billion in 2025 and is expected to be worth around USD 29.49 billion...
Merck KGaA (XTRA:MRK): Exploring Valuation Gaps and Growth Narratives in 2024
Merck KGaA (XTRA:MRK) shares have seen some ups and downs recently, which has sparked questions about the forces shaping the pharmaceutical and life sciences firm's valuation. Investors are keeping an...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.